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1242Objective: Thoracic endovascular aortic repair, although physiologically well tolerated, may fail to confer sig-
nificant survival benefit in some high-risk patients. In an effort to identify patients most likely to benefit from
intervention, the present study sought to determine the risk factors for 1-year mortality after thoracic endovas-
cular aortic repair.
Methods: A retrospective review was performed on prospectively collected data from all patients undergoing
thoracic endovascular aortic repair from 2002 to 2010 at a single institution. Univariate analysis and multivariate
Cox proportional hazards regression analysis were used to identify risk factors associated with mortality within 1
year after thoracic endovascular aortic repair.
Results: During the study period, 282 patients underwent at least 1 thoracic endovascular aortic repair; index
procedures included descending aortic repair (n ¼ 189), hybrid arch repair (n ¼ 55), and hybrid thoracoabdo-
minal repair (n¼ 38). The 30-day/in-hospital mortality was 7.4% (n¼ 21) and the overall 1-year mortality was
19% (n¼ 54). Cardiopulmonary pathologies were the most common cause of nonperioperative 1-year mortality
(22%, n¼ 12). Multivariate modeling demonstrated 3 variables independently associated with 1-year mortality:
age older than 75 years (hazard ratio, 2.26; P ¼ .005), aortic diameter greater than 6.5 cm (hazard ratio, 2.20;
P ¼ .007), and American Society of Anesthesiologists class 4 (hazard ratio, 1.85; P ¼ .049). A baseline creat-
inine greater than 1.5 mg/dL (hazard ratio, 1.79; P ¼ .05) and congestive heart failure (hazard ratio, 1.87;
P ¼ .08) were also retained in the final model. These 5 variables explained a large proportion of the risk of
1-year mortality (C statistic ¼ 0.74).
Conclusions: Age older than 75 years, aortic diameter greater than 6.5 cm, and American Society of Anesthe-
siologists class 4 are independently associated with 1-year mortality after thoracic endovascular aortic repair.
These clinical characteristics may help risk-stratify patients undergoing thoracic endovascular aortic repair
and identify those unlikely to derive a long-term survival benefit from the procedure. (J Thorac Cardiovasc
Surg 2013;145:1242-7)Thoracic endovascular aortic repair (TEVAR) is being in-
creasingly used to treat a variety of thoracic aortic patholo-
gies.1 The short-term benefits of TEVAR versus open repair
have been demonstrated and include decreased operative
mortality,2-5 decreased morbidity,2,5,6 and decreased
hospital length of stay.6 The low perioperative risk of
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The Journal of Thoracic and Cardiovascular Surpatients, including higher risk patients who might not
have been offered traditional open repair in the past.7,8 It
has been previously shown in patients undergoing
endovascular abdominal aortic aneurysm repair (EVAR)
that the early perioperative benefits of an endovascular
approach were not sustained in longer term analyses.9
Therefore, although physiologically well tolerated, some
patients offered TEVAR may still experience significant
mortality risk beyond the perioperative period10 and, thus,
not obtain an overall survival benefit from the procedure.
The risk factors for death after TEVAR have been partially
elucidated, including the predictors of 30-day and long-term
mortality.11,12 However, many patients survive the initial
postoperative period, but die after discharge and within 1
year of surgery.10 The risk factors for death within this
period have yet to be specifically defined. The identification
of such risk factors might lead to more appropriate applica-
tion of TEVAR, improved risk stratification, and better pa-
tient prognostic information. Therefore, the objective of the
present study was to determine the risk factors for 1-year
mortality after TEVAR. We hypothesized that specificgery c May 2013
Abbreviations and Acronyms
ASA ¼ American Society of Anesthesiologists
EVAR ¼ endovascular abdominal aortic
aneurysm repair
TEVAR ¼ thoracic endovascular aortic repair
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ables are associated with 1-year mortality after TEVAR.A
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DMETHODS
Patients and Data Source
A retrospective review was performed on prospectively collected data
from all patients undergoing TEVAR from May 2002 to December 2010
at a single referral institution. Preoperative, intraoperative, and postopera-
tive variables were abstracted from the Duke Thoracic Aortic Surgery Da-
tabase, a prospectively maintained clinical registry of all patients
undergoing thoracic aortic surgery at Duke University Medical Center
(Durham, NC). For patients with multiple TEVAR procedures, the first
was used as the index procedure for the time-to-event analyses. The insti-
tutional review board of Duke University reviewed and approved the study,
and the need for individual patient consent was waived. All procedures and
management were a part of routine clinical care as determined by the clin-
ical care team.
TEVAR Procedures
TEVAR patient selection, techniques of device delivery and deploy-
ment, and postoperative surveillance have been previously described.13-
15 All 5 currently Food and Drug Administration–approved thoracic stent
grafts and the investigational Zenith TX2-LP (Cook Medical, Blooming-
ton, Ind) device were used. The indications for each TEVAR procedure
were classified as degenerative aneurysm (including penetrating athero-
sclerotic ulcers), acute and chronic dissection, or acute blunt traumatic aor-
tic injury (transection). The procedures were further classified as
descending-only repair,16 hybrid arch repair (aortic arch debranching
with aortic endograft coverage),13 and hybrid thoracoabdominal repair
(visceral abdominal debranching with aortic endograft coverage).14,17
Variables and Outcomes
The primary study outcome was 1-year mortality, defined as death oc-
curring between postoperative day 0 and postoperative day 365. The causes
of death were classified as perioperative (death within 30 days of TEVAR
or within the same hospitalization as the initial TEVAR procedure), aortic-
related, cardiopulmonary, cancer, sepsis, failure to thrive, neurologic,
other, and unknown. The cause of death was determined by autopsy, med-
ical records, or family interview. The present report included all data col-
lected through the patients’ 1-year follow-up visit, a review of outside
medical records, or patient/family telephone interview in the case of miss-
ing 1-year follow-up information. Deaths from all causes were included in
the analysis. In addition, the Social Security Death Index was queried
(available from http://ssdi.rootsweb.com/) to confirm all patient deaths.
Those variables previously identified in peer-reviewed litera-
ture11,12,18,19 as potential predictors of outcome in aortic surgery were
included as candidate variables for the analysis. The final list of
preoperative model variables assessed included age, race, gender, body
mass index, left ventricular ejection fraction (from echocardiography,
cardiac magnetic resonance imaging, or cardiac catheterization), aortic
diameter, preoperative hemoglobin concentration, preoperative serum
creatinine level, congestive heart failure, a history of myocardial
infarction, gastroesophageal reflux disease, peripheral vascular disease,The Journal of Thoracic and Carsteroid use, angiotensin-converting enzyme inhibitor or angiotensin II re-
ceptor blocker use, a history of alcohol abuse, type 1 or 2 diabetes, hyper-
tension, a history of stroke, chronic obstructive pulmonary disease,
restrictive lung disease, a history of previous aortic surgery, the presence
of aortic-related symptoms (ie, chest pain, back pain, malperfusion), Amer-
ican Society of Anesthesiologists (ASA) physical status classification sys-
tem, indication for procedure, urgency of case, and preoperative white
blood cell count. The intraoperative variables assessed included procedure
performed, number of endografts placed, extent of aortic pavement, endog-
raft type, subclavian artery coverage, and use of cerebrospinal fluid
drainage.
Statistical Analysis
The preoperative and intraoperative variables were compared between
patients who died within 1 year of TEVAR (event group) and thosewho sur-
vived until at least 1 year after TEVAR (nonevent group) using univariate
linear regression analysis and chi-square tests for continuous and discrete
variables, respectively. Continuous variables were checked for normality
using Kolmogorov-Smirnov tests and are presented as the mean standard
deviation. Categorical variables are presented as percentages (raw num-
bers). For the variable ‘‘aortic diameter,’’ a threshold of greater than 6.5
cm was chosen because this value represented the 75th percentile within
the distribution of aortic diameters in the cohort. We have previously per-
formed this analysis using aortic diameter as a continuous variable and
found similar results. We chose to use aortic diameter as a categorical,
rather than a continuous, variable to give the reader a more clinically rele-
vant cutoff to use when risk stratifying these patients.
Multivariable Cox proportional hazards regression analysis was then
used to determine the risk factors for 1-year mortality. Variables with
a nominal P<.1 on univariate analysis were entered into the multivariable
model. The maximum time-to-event was set at 365 days, and the entire
study population was therefore censored at that point. Events were defined
as death occurring within 1 year of TEVAR. Statistical analysis was per-
formed by 2 authors (D.M.C. and A.A.S.) using SAS, version 9.1 (SAS In-
stitute, Cary, NC).RESULTS
A total of 316 procedures were performed on 282 pa-
tients. The preoperative and intraoperative characteristics
of the study population are listed in Tables 1 and 2, respec-
tively. Indications for the index TEVAR procedure included
degenerative aneurysm (n ¼ 183), aortic dissection
(n ¼ 82), and blunt aortic injury (n ¼ 17). The procedures
performed included descending aortic repair (n ¼ 189), hy-
brid arch repair (n ¼ 55), and hybrid thoracoabdominal re-
pair (n ¼ 38). Concomitant procedures were performed in
21% (n ¼ 58) and most frequently included carotid-
subclavian bypass (n ¼ 26). Aortic-related reintervention
was required in 9.6% (n ¼ 27) of the patients in the initial
year after TEVAR. Follow-up was 100% complete.
The 30-day/in-hospital mortality was 7.4% (n¼ 21), and
the overall 1-year mortality was 19% (n ¼ 54). Cardiopul-
monary pathologies were the most common cause of non-
perioperative mortality within 1 year of TEVAR (22% of
all 1-year deaths [n ¼ 12]; Table 3). The patient variables
associated with 1-year mortality on univariate analysis
were age older than 75 years (P<.001), congestive heart
failure (P ¼ .03), peripheral vascular disease (P ¼ .02),
a history of stroke (P ¼ .04), creatinine greater than 1.5diovascular Surgery c Volume 145, Number 5 1243
TABLE 1. Preoperative patient characteristics
Variable All patients (n ¼ 282) Nonevent group (n ¼ 228) Event group (n ¼ 54) P value*
Age>75 y 24% (68) 20% (45) 43% (23) .0004
Sex (male) 59% (166) 57% (131) 65% (35) .32
Race (white) 65% (182) 62% (142) 74% (40) .10
BMI>30 kg/m2 27% (76) 29% (66) 19% (10) .12
LVEF (%) 53  6 53  5 51  8 .30
CHF 12% (33) 10% (22) 20% (11) .03
History of MI 13% (36) 11% (25) 20% (11) .06
Hypertension 83% (233) 82% (187) 85% (46) .58
ACEI/ARB use 40% (113) 38% (86) 50% (27) .10
PVD 23 (64%) 20% (45) 35% (19) .02
History of stroke 11% (30) 9% (20) 19% (10) .04
Diabetes 13% (38) 14% (33) 9% (5) .31
Smoking 56% (157) 58% (131) 48% (26) .18
COPD 28% (80) 28% (63) 31% (17) .57
Restrictive lung disease 2% (7) 2% (5) 4% (2) .62
GERD 33% (93) 31% (71) 41% (22) .18
Steroid use 3% (9) 3% (7) 4% (2) .68
Alcohol abuse 7% (20) 8% (19) 2% (1) .14
Hemoglobin (g/dL) 12  2 12  2 12  2 .79
Creatinine>1.5 mg/dL 21% (60) 18% (41) 35% (19) .006
Preoperative WBC count>10K 19% (50) 19% (39) 22% (11) .55
ASA class 4 (vs 3) 51% (132) 47% (96) 71% (36) .002
Previous aortic surgery 39% (111) 37% (85) 48% (26) .14
Presence of aortic-related symptoms 49% (137) 49% (112) 46% (25) .69
Aortic diameter>6.5 cm 25% (71) 20% (45) 48% (26) <.0001
Indication .02
Aneurysm 65% (183) 61% (140) 80% (43)
Dissection 29% (82) 31% (71) 20% (11)
Blunt aortic injury 6% (17) 7% (17) 0% (0)
Procedure status .99
Elective 62% (171) 62% (139) 62% (32)
Urgent 25% (68) 25% (55) 25% (13)
Emergent 13% (36) 13% (29) 13% (7)
Data presented as percentages, with numbers in parentheses, or mean standard deviation.BMI, Body mass index; LVEF, left ventricular ejection fraction;CHF, congestive heart
failure;MI, myocardial infarction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; PVD, peripheral vascular disease; COPD, chronic ob-
structive pulmonary disease;GERD, gastroesophageal reflux disease;WBC, white blood cell; ASA, American Society of Anesthesiologists. *P value for univariate comparison of
living versus 1-year mortality groups.
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Dmg/dL (P¼ .006), ASA class 4 (P¼ .002), and aortic diam-
eter greater than 6.5 cm (P< .001; Tables 1 and 2). The
1-year mortality differed according to the indication for
TEVAR, with patients who underwent TEVAR for blunt
aortic injury having 0% 1-year mortality and those under-
going TEVAR for aortic dissections and degenerative aneu-
rysms having 13% and 24% 1-year mortality, respectively
(P ¼ .02). The type of TEVAR procedure performed was
also associated with 1-year mortality, with patients under-
going hybrid arch repairs having the greatest 1-year mortal-
ity (29%), followed by 27% for hybrid thoracoabdominal
repair and 15% for descending-only repair (P ¼ .03).
Multivariable modeling demonstrated that 3 of these vari-
ables were independently associated with 1-year mortality:
age older than 75 years (hazard ratio [HR], 2.26; 95% con-
fidence interval [CI], 1.28-3.98; P ¼ .005), aortic diameter
greater than 6.5 cm (HR, 2.20; 95% CI, 1.25-3.88;1244 The Journal of Thoracic and Cardiovascular SurP ¼ .007), and ASA class 4 (HR, 1.85; 95% CI, 1.003-
3.43; P ¼ .049; Table 4). A baseline creatinine greater
than 1.5 mg/dL (HR, 1.79; 95% CI, 0.99-3.21; P ¼ .05)
and congestive heart failure (HR, 1.87; 95% CI,
0.93-3.80; P ¼ .08) were also retained in the final model.
These 5 variables explained a large proportion of the risk
of 1-year mortality (C statistic ¼ 0.74).
DISCUSSION
TEVAR has been used to treat a variety of pathologic en-
tities of the thoracic aorta. Because the procedure is gener-
ally well tolerated from a physiologic standpoint, even in
many patients who would not be considered candidates for
conventional open repair, the application of this technology
appears to be increasing.1 However, some patients offered
TEVAR may suffer significant 1-year mortality10 and thus
not obtain a meaningful survival benefit from the procedure.gery c May 2013
TABLE 2. Intraoperative patient characteristics
Variable All patients (n ¼ 282) Nonevent group (n ¼ 228) Event group (n ¼ 54) P value*
TEVAR .03
Descending 67% (189) 71% (161) 52% (28)
Hybrid arch 20% (55) 18% (40) 28% (15)
Hybrid TAAA 13% (38) 12% (27) 20% (11)
Aortic pavement .71
Left subclavian to T6 41% (116) 41% (94) 41% (22)
Mid-thoracic aorta to celiac axis 11% (32) 12% (27) 9% (5)
Left subclavian artery to celiac axis 27% (76) 28% (63) 24% (13)
Other 21% (58) 19% (44) 26% (14)
Stent graft type .78
Gore TAG/C-TAG 59% (167) 59% (135) 59% (32)
Medtronic Talent/Valiant 13% (37) 14% (31) 11% (6)
Zenith TX2/TX2-LP 19% (54) 19% (44) 19% (10)
Other 1% (3) 1% (3) 0% (0)
Combination 7% (21) 7% (15) 11% (6)
No. of stent grafts 1.9  1.0 1.8  0.96 2.2  1.1 .28
CSF drain 21% (58) 19% (44) 26% (14) .29
Subclavian artery coverage 54% (152) 54% (124) 52% (28) .74
Data presented as percentages, with numbers in parentheses, or mean  standard deviation. TEVAR, Thoracic endovascular aortic repair; TAAA, thoracoabdominal aortic aneu-
rysm; CSF, cerebrospinal fluid. *P value for univariate comparison of living versus 1-year mortality groups.
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DGoodney and colleagues20 recently examined the short-
and long-term survival after open and endovascular de-
scending thoracic aortic aneurysm repair in the Medicare
population. They found that the short-term survival advan-
tage of TEVAR compared with open repair was lost within 2
years of surgery.20 Furthermore, the long-term (5-year) sur-
vival was shown to be worse after TEVAR than after open
repair, even after adjustment for patient comorbidities.20
Although unknown, these recent data may indicate that cer-
tain patients who would not have traditionally been offered
open repair are now being offered TEVAR and that these pa-
tients are not obtaining a survival benefit from the proce-
dure. The investigators concluded that additional work is
needed to identify this group of patients unlikely to benefit
from TEVAR.20 The present study has addressed this issue
by delineating several preoperatively identifiable risk fac-
tors that might lead to more appropriate application of
TEVAR.
Previous work has documented significant interval mor-
tality within 1 year after conventional thoracoabdominalTABLE 3. Causes of 1-year mortality
Cause % (n)
Perioperative* 39 (21)
Cardiopulmonary 22 (12)
Aortic related 9 (5)
Neurologic 6 (3)
Failure to thrive 6 (3)
Sepsis 4 (2)
Other 7 (4)
Unknown 7 (4)
*Thirty-day/in-hospital mortality after thoracic endovascular aortic repair.
The Journal of Thoracic and Caraortic aneurysm repair,21 findings that led the investigators
to suggest that 1-year mortality data should play a role in
clinical decision making for thoracoabdominal aortic aneu-
rysm repair. The results of the present study, with nearly
20% mortality within 1 year postoperatively, extend this
finding to thoracic endovascular repair and suggest a similar
logic should apply to TEVAR as well. Because the preva-
lence of thoracic aortic disease increases with age,22 and be-
cause the U.S. population aged older than 65 years is
expected to increase by 50% within the next decade,23
the overall need for TEVAR procedures is likely to increase.
Thus, given this increased need among an older and sicker
population, a risk model examining 1-year mortality
should prove helpful to clinicians and patients and their
families in identifying patients unlikely to benefit from
repair.
Furthermore, given the expense of these procedures with
typical device costs of $10,000 to 15,000 per component,
economic questions regarding appropriate use are likely
to arise in this era of increasing healthcare costs. Although
a rigorous cost-effectiveness analysis has not been per-
formed for TEVAR, given the high cost of the devices,TABLE 4. Multivariate model for 1-year mortality
Variable HR (95% CI) P value
Age>75 y 2.26 (1.28-3.98) .005
Aortic diameter>6.5 cm 2.20 (1.25-3.88) .007
ASA class 4 1.85 (1.003-3.43) .049
Creatinine>1.5 mg/dL 1.79 (0.99-3.21) .05
Congestive heart failure 1.87 (0.93-3.80) .08
HR, Hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiolo-
gists.
diovascular Surgery c Volume 145, Number 5 1245
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Dsurgical implantation, and radiographic follow-up, it is un-
likely that these costs would meet accepted cost-
effectiveness thresholds24 if patients experience less than
1 year of added survival. In the abdominal aortic aneurysm
data, EVAR quickly becomes cost-ineffective when mortal-
ity rates from the procedure increase to more than 4.4%.25
Furthermore, given that the estimated yearly risk of death is
10.8% for a patient with a greater than 6-cm thoracic aneu-
rysm,26 the vast majority of patients who undergo elective
TEVAR and die within 1 year of intervention experience
no survival benefit from the procedure.
To our knowledge, this is the largest study describing the
risk factors for 1-year mortality after TEVAR. The present
study included patients undergoing descending TEVAR
only and patients undergoing more complex hybrid arch
and hybrid thoracoabdominal aortic aneurysm repairs. Al-
though the inclusion of hybrid repairs adds heterogeneity
to the study population, all 3 treatment groups were in-
cluded, given that all share the common intervention of en-
dograft placement in the thoracic aorta. Furthermore, the
vast majority of all 3 of these procedures are performed to
treat the same 2 disease processes, namely degenerative an-
eurysm and aortic dissection. Finally, most published
TEVAR series have included hybrid cases, which can con-
stitute one third or more of the patients; therefore, including
these patients represents ‘‘real world’’ risk stratification for
TEVAR as used in clinical practice.15
The present report has demonstrated that age older than
75 years, aortic diameter greater than 6.5 cm, and ASA class
4 are associated with 1-year mortality after TEVAR. The
finding of aortic diameter as an independent risk factor
for 1-year mortality has support from previous studies.
Chung and colleagues11 found aneurysm size to be a predic-
tor of mortality at any point after TEVAR in a general group
of TEVAR patients, as well as in a subset of patients with
asymptomatic, nonruptured degenerative aneurysms. Dilla-
vou andMakaroun19 showed increasing aneurysm size to be
a predictor of major adverse events27 in patients undergoing
endovascular or open thoracic aortic repair (P<.001), al-
though aneurysm size did not reach statistical significance
in the endovascular group alone (P ¼ .082). Patients pre-
senting with a larger aortic size frequently manifest more
advanced aortic disease, which can be associated with
greater atherosclerotic burden,28 as well as greater systemic
disease burden, such as chronic obstructive pulmonary dis-
ease. In the present study, patients with chronic obstructive
pulmonary disease had larger aneurysms, although this dif-
ference did not reach statistical significance (6.0 vs 5.6 cm,
P ¼ .13).
The ASA class was associated with 1-year mortality and,
similarly, has been associated with morbidity and mortality
after a variety of surgical procedures. In patients undergoing
TEVAR for type B dissection, ASA class has been associ-
ated with postintervention mortality.29 ASA class has also1246 The Journal of Thoracic and Cardiovascular Surbeen associated with increased morbidity, mortality, and
hospitalization rates in patients undergoing EVAR.30 The
present data thus extend the known prognostic value of
ASA class to 1-year mortality in patients undergoing
TEVAR.
Our finding of increased mortality in patients more than
75 years old was expected. Czerny and colleagues18 found
a near doubling of mortality (35% vs 18%) in patients older
than 75 years after TEVAR during a median follow-up of 36
months. Numerous other studies have shown that increasing
age is a risk factor for mortality after TEVAR.31-33
Cardiopulmonary pathologies were the most common
cause of nonperioperative 1-year mortality in the present
study (22%). This appears consistent with the available
data on early and late causes of post-TEVAR mortality.
For example, in the series by Chung and colleagues,11 car-
diopulmonary causes were responsible for 43% of the
30-day mortality and 24% of the mortality more than 30
days after TEVAR. In the cohort reported on by Khoynez-
had and colleagues,12 39% of early deaths were from myo-
cardial infarction and 47% of late (>30-day) deaths were
from myocardial infarction or pneumonia. This high inci-
dence of cardiopulmonary causes of mortality was not un-
expected, given the similar risk factors for cardiac,
pulmonary, and many aortic diseases.
Recent data from the EVAR 1 trial9 examining the long-
term outcomes of endovascular versus open abdominal
aortic aneurysm repair showed that secondary aortic rupture
after endovascular repair was likely responsible for much of
the long-term increased aneurysm-related mortality with
this treatment strategy. These findings contrast with the
present TEVAR report in which aortic-related 1-year mor-
tality was modest, accounting for 9% of nonperioperative
1-year deaths. The present results are more similar to those
from the Dutch Randomised Endovascular AneurysmMan-
agement (DREAM) trial34 of EVAR, in which aneurysm
rupture and graft-related complications were infrequent
causes of longer term mortality.
The present study has several limitations. First, the study
did not include a control group of nonoperative or open sur-
gical management with which to compare the TEVAR
1-year survival data. Second, the cause of death was un-
known for 4 patients, although the follow-up data were
100% complete. These deaths were generally unwitnessed
sudden deaths at home. Finally, although the 5 variables in
the multivariable model explain the large proportion
(C statistic ¼ 0.74) of risk for 1-year mortality after
TEVAR, they do not explain all the risk, and other, as yet
unknown, variables could also be important predictors. Fur-
thermore, the ability to use the model as a meaningful pre-
dictor of risk for any given patient requires validation,
although the present study represents the largest series to
date reporting the risk factors for 1-year mortality after
TEVAR, has more than 10 events per model variable, andgery c May 2013
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Dhas confirmed many risk factors for mortality previously
identified by other TEVAR studies. Finally, there are likely
postoperative variables that also affect 1-year mortality that
the present study did not attempt to identify.
CONCLUSIONS
In the present single-institution series, age older than 75
years, aortic diameter greater than 6.5 cm, and ASA class 4
were associated with increased mortality within 1 year of
TEVAR. These clinical factors should be taken into account
when weighing the risks and benefits of pursuing TEVAR as
a treatment option and when providing patients with prog-
nostic information. The results may help better risk stratify
patients and identify those less likely to derive a long-term
survival benefit from TEVAR.
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